TherapeuticsMD (TXMD) Capital Expenditures (2011 - 2023)

TherapeuticsMD (TXMD) has reported Capital Expenditures for 13 consecutive years, with $2.3 million the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Capital Expenditures fell 69.65% year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2023 stood at $1.1 million (down 85.25% YoY), and the FY2023 full-year result was $1.1 million, down 85.25% from the prior year.
• Capital Expenditures grew to $2.3 million in Q4 2023 per TXMD's latest filing, from -$721000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $7.6 million in Q4 2022 and bottomed at -$721000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $636277.8 across 5 years, with a median of $41500.0 in 2021.
• The sharpest annual moves came in 2019 and 2023: Capital Expenditures soared 4745.24% in 2019, then slumped 2200.0% in 2023.
• Over 5 years, Capital Expenditures stood at $360587.0 in 2019, then plunged by 53.41% to $168000.0 in 2020, then slumped by 141.67% to -$70000.0 in 2021, then jumped by 10978.57% to $7.6 million in 2022, then slumped by 69.65% to $2.3 million in 2023.
• According to Business Quant data, Capital Expenditures over the past three periods registered $2.3 million, -$721000.0, and -$483000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.